International Symposium
on

VIROLOGICAL ASPECTS
OF THE SAFETY OF BIOLOGICAL PRODUCTS

Proceedings of a Symposium
organized by the
International Association of Biological Standardization
and Ares Serono Symposia
held at the
Zoological Society of London
Regents Park, London, England

November 8-9, 1990

34 figures and 54 tables
TABLE OF CONTENTS

Session I

SAFETY OF BIOLOGICALS: REGULATORY APPROACH

Co-chairmen: F. Horaud (F)
J. Löwer (D)

F. Horaud (Paris): Introductory remarks: viral safety of biologicals ........................................... 3

J. C. Petricciani (Washington, DC): Regulatory philosophy and acceptability of cells for the production of biologicals .......................................................... 9

D.I. Magrath (WHO, Geneva): Safety of vaccines produced in continuous cell lines .............. 17

Patricia Brunko and F. Sauer (Brussels): EEC legislation of medicinal products of biological origin ................................................................. 21

Session II

VIRUS INACTIVATION

Co-chairmen: R. Kurth (D)
J.C. Petricciani (USA)

J.L. Melnick (Houston, TX): Virus inactivation: lessons from the past ..................................... 29

F. Brown (Guildford): An overview of the inactivation of FMDV and the implications when residual virus is present in vaccines ................................................................. 37

B. Horowitz (New York, NY): Specific inactivation of viruses which can potentially contaminate blood products ................................................................. 43

Session III

BSE AND RELATED AGENTS (1)

Co-chairmen: J.L. Melnick (USA)
P. Minor (UK)

S.B. Prusiner (San Francisco, CA): Molecular biology of prions causing infectious and genetic encephalopathies of humans as well as scrapie of sheep and BSE of cattle .................... 55

R.H. Kimberlin (Edinburgh): An overview of bovine spongiform encephalopathy .............. 75

Session IV

BSE AND RELATED AGENTS (2)

Co-chairmen: G. Vicari (I)
D. Magrath (CH)

R.G. Will (Edinburgh): An overview of Creutzfeldt-Jakob disease associated with the use of human pituitary growth hormone ................................................................. 85
M. Pocchiari (Lecce): Methodological aspects of the validation of purification procedures of human/animal-derived products to remove unconventional slow viruses .......................... 87

D.M. Taylor (Edinburgh): Inactivation of BSE agent .................................................... 97

Session V

RETROVIRUSES

Co-chairmen: J. Obijeski (USA)
B. Mahy (USA)

R. Kurth, M. Baier, Doris Binninger, K. Cichutek, J. Löwer and S. Norley (Langen): Epidemiology and pathogenicity of human retroviruses .......................................................... 105

Rodica Emanoil-Ravier, Frida Hojman, Martine Servenay, J. Lesser, A. Bernardi and J. Peries (Paris and Gif-sur-Yvette): Biological and molecular studies of endogenous retrovirus-like genes in Chinese hamster cell lines ...................................................... 113

K.P. Anderson, Yolanda S. Lie, Mari-Anne Low, S.R. Williams, F. Wurm and M. Dinowitz (San Francisco, CA): Defective endogenous retrovirus-like sequences and particles of Chinese hamster ovary cells ................................................................. 123

C.J. Marcus-Sekura (Bethesda, MD): Validation of removal of human retroviruses ........ 133

D. Onions and Gillian Lees (Glasgow): Human retroviruses and herpesviruses: problems and solutions in safety testing of biologicals ......................................................... 145

J. Hilfenhaus, J.P. Gregersen, H. Müller, T. Nowak and W. Pranter (Marburg): Inactivation of retroviruses in biologicals manufactured for human use ....................... 159

Session VI

VIRAL CONTAMINATION AND DETECTION (1)

Co-chairmen: R. Hay (USA)
H. Agut (F)

G.A. Erickson, S.R. Bolin and J.G. Landgraf (Raleigh, NC and Ames, IA): Viral contamination of fetal bovine serum used for tissue culture: risks and concerns ......................... 173

R.L. Levings and S.J. Wessman (Ames, IA): Bovine viral diarrhea virus contamination of nutrient serum, cell cultures and viral vaccines .................................................. 177

B.W.J. Mahy, Clare Dykewicz, Susan Fisher-Hoch, S. Ostroff, Margaret Tipple and A. Sanchez (Atlanta, GA): Virus zoonoses and their potential for contamination of cell cultures ... 183

Session VII

VIRAL CONTAMINATION AND DETECTION (2)

Co-chairmen: F. Brown (UK)
P. Adamowicz (F)

R.J. Hay (Rockville, MD): Operator-induced contamination in cell culture systems ........ 193

J.S. Robertson (Potters Bar): New molecular approaches for detecting viral genomes ........ 205

H. Agut and J.M. Huraux (Paris): Correlations between virus infection and pathogenicity in humans ................................................................................................................. 211
# Session VIII

**ROUND TABLE ON: REGULATORY ASPECTS OF VIRUS SAFETY**

*Co-chairmen:* G. Schild (UK)  
P. Albrecht (USA)

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. Löwer (Langen)</td>
<td>Virological aspects of the quality control of biologicals: quantitative considerations</td>
<td>221</td>
</tr>
<tr>
<td>G. Vicari (Roma)</td>
<td>Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider</td>
<td>227</td>
</tr>
<tr>
<td>P. Minor (Potters Bar)</td>
<td>Virological aspects of the quality control of human monoclonal antibodies</td>
<td>233</td>
</tr>
<tr>
<td>F. Horaud (Paris)</td>
<td>European project concerning the guidelines on medicinal products derived from human blood and plasma</td>
<td>237</td>
</tr>
<tr>
<td>V.P. Grachev (WHO, Geneva)</td>
<td>Viral safety of biological products in WHO policy</td>
<td>241</td>
</tr>
<tr>
<td>G.C. Schild (Potters Bar)</td>
<td>EC Ad Hoc Working Party on Biotechnology/Pharmacy</td>
<td>247</td>
</tr>
</tbody>
</table>

**SUMMARY OF THE MEETING**

Summary of the meeting ......................................................... 253